Research Associate
About the job
- Ability to work with animals in a laboratory setting.
- Ability to follow and accurately execute standard operating procedures.
- Experience in or ability to learn a variety of animal-based research techniques.
- Experience in or ability to learn general laboratory techniques such as micropipetting and aseptic technique.
- Experience with Microsoft Word and Excel.
- Ability to lift 30 pounds and perform moderate manual labor.
- A Bachelor of Science or Bachelor of Arts degree, or an Associate's degree with experience in a related field.
- Zero to two or more years of experience in a related field.
- Perform cage changes, clean cages and racks, feed animals, wean litters, identify animals, and monitor animals in accordance with The Guide for the Care and Use of Laboratory Animals.
- Operate and maintain the Animal Facility according to standard operating procedures to ensure compliance with the Institutional Animal Care and Use Committee.
- Maintain inventory and organization of Animal Facility supplies and order supplies as required.
- Report Animal Facility status and communicate daily with the supervisor.
- Administer injections through routes such as subcutaneous and intraperitoneal injection.
- Collect blood samples.
- Perform necropsies for tissue collection.
- Monitor tumor growth and measure tumor size.
- Learn advanced in vivo techniques and assist with development of animal models of inflammation.
- Assist with in vitro tissue and sample preparation.
- Perform in vitro assays such as enzyme-linked immunosorbent assays and cell culture.
- Collect and organize data.
- Perform additional husbandry and research support duties as required.
- Maintain daily records.
- AALAS certification is a plus.
- Strong communication and organizational skills.
- Ability to work independently and as part of a team.
- Excellent time management skills.
About the company
Celldex develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that blocks KIT signaling to reduce mast cell activity and inflammation, with additional antibodies in development that engage the immune system or modulate disease pathways. It differentiates itself by concentrating on KIT/mast cell biology within antibody therapies and pursuing a mix of partnerships, licensing, and own products. Its goal is to bring therapies to patients that lower inflammation and autoimmunity by targeting mast cells and related pathways.
Company Size
201-500
Company Stage
IPO
Headquarters
Hampton, New Jersey
Founded
1983
Get referred to Celldex Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Sept. 22, 2026 Phase 3 EMBARQ-CSU1 and CSU2 met all primary endpoints.
- June 30, 2026 cash reached $717.6 million after April's $323.8 million offering.
- Management plans a 2027 BLA submission, creating a near-term regulatory catalyst.
What critics are saying
- July 2026 prurigo nodularis failure killed one barzolvolimab growth path immediately.
- Aug. 24, 2026 shareholder investigation threatens governance distraction and litigation costs.
- One program, barzolvolimab, still drives value; a CSU safety setback would cripple Celldex.
What makes Celldex Therapeutics unique
- Barzolvolimab targets KIT-positive mast cells, a mechanism few allergy drugs attack directly.
- Phase 3 EMBARQ-CSU enrolled 1,939 patients, giving Celldex unusually deep CSU data.
- CDX-622 combines TSLP neutralization with mast-cell depletion, broadening its immunology platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Paid Holidays
- Paid Vacation
- Paid Sick Leave
- 401(k) Retirement Plan